Nonalcoholic fatty liver disease (NAFLD), sarcopenia and sarcopenic obesity (SO) are
highly prevalent conditions that may coexist, especially in the aging population, without any …

Objective Sarcopenia has been recognized as the third category of disabling complications
in patients with type 2 diabetes mellitus (T2DM), in addition to micro-and macrovascular …

Aim Use of sodium‐glucose co‐transporter‐2 inhibitors (SGLT2is) for glycaemic control is
increasing in individuals with type 2 diabetes (T2D) for their additional benefits on heart …

Body composition changes that occur during aging, such as loss of lean mass, are
unfavorable at metabolic level and they can explain, in part, the appearance of certain age …

Sarcopenia is an age-related clinical complaint characterized by the progressive
deterioration of skeletal muscle mass and strength over time. Type 2 diabetes (T2D) is …

Sarcopenia is a disease characterized by the progressive loss of skeletal muscle mass and
function that occurs with aging. The progression of sarcopenia is correlated with the onset of …

Obesity is a chronic disease characterised by excess adiposity, which impairs health. The
high prevalence of obesity raises the risk of long-term medical complications including type …

This review will try to elucidate the interconnected pathophysiology of sarcopenia and type 2
diabetes (T2D) and will try to identify a common pathway to explain their development. To …

Background and aims Sodium glucose co-transporter 2 (SGLT2)-inhibitors were developed
as glucose-lowering drugs. Surprisingly, SGLT2-inhibitors also reduced risk of …

SGLT-2i are the new standard of care for diabetic kidney disease (DKD), but previous
studies have not included patients on kidney replacement therapy (KRT). Due to their high …